Defibrotide Therapy for SARS-CoV-2 ARDS.

ABSTRACT:

Background

SARS-CoV-2-related ARDS is associated with endothelial dysfunction and profound dysregulation of the thrombotic-fibrinolytic pathway. Defibrotide is a polyanionic compound with fibrinolytic, antithrombotic, and antiinflammatory properties.

Research question

What is the safety and tolerability of defibrotide in patients with severe SARS-CoV-2 infections?

Study design and methods

We report a prospective, open-label, single-center safety trial of defibrotide for the management of SARS-CoV-2-related ARDS. Eligible participants were 18 years of age or older with clinical and radiographic signs of ARDS, no signs of active bleeding, a serum D-dimer of more than twice upper limit of normal, and positive polymerase chain reaction-based results for SARS-CoV-2. Defibr

SUBMITTER: Frame D 

PROVIDER: S-EPMC8993696 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature